Infectious disease
It was yet another busy week for clinical trial news. Here’s a look.
A growing number of studies show that though natural immunity can work, hybrid immunity through vaccination could be better. They urge faster vaccination drives.
Earlier this month, Catalent announced plans to add 500–600 jobs in Bloomington, Ind., one of its Moderna and Johnson & Johnson COVID-19 vaccine manufacturing sites.
The CDC supported the FDA’s approval of mixing and matching vaccines, where eligible populations can take a booster shot from another brand different from their initial series.
The Pfizer-BioNTech mRNA COVID-19 vaccine is reportedly the top vaccine used globally. Here’s a look at today’s highlights.
The U.S. FDA approved the use of Moderna’s and Janssen’s COVID-19 vaccines as a booster dose after their primary versions are completed.
Winter is quickly approaching in the U.S. Vaccine makers aren’t taking a wait-and-see approach but actively preparing for what may come next.
A subtype of the Delta variant might be rising, although it’s not yet clear if it’s more transmissible or lethal than the original Delta variant. Read on for that and more COVID-19 news.
Novavax is having problems getting its COVID-19 vaccine to the finish line. Shares plunged more than 23% in premarket trading today after reports that it is having manufacturing problems.
The CDC has warned that COVID-19 during pregnancy can result in preterm birth and other negative outcomes, including stillbirths.
PRESS RELEASES